Cancer of unknown primary, favourable subsets: lines of therapy
7 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Work-up | Histology with directed immunohistochemistry, CT of chest, abdomen and pelvis, sex-specific examinations and tumour markers, PET-CT for cervical node squamous carcinoma and single-site disease. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 95 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Axillary node adenocarcinoma in a woman | Treat as node-positive breast cancer: axillary dissection, breast radiotherapy or mastectomy, systemic therapy by receptor status. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 93 | |
| All comers | Peritoneal serous carcinoma in a woman | Treat as advanced ovarian cancer: cytoreductive surgery and carboplatin-paclitaxel with maintenance as indicated. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 82 | |
| All comers | Cervical node squamous carcinoma | Treat as head and neck cancer: HPV and EBV testing, neck dissection or chemoradiotherapy with cisplatin. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 93 | |
| All comers | Midline poorly differentiated carcinoma in a young man | Treat as extragonadal germ cell tumour with cisplatin-based combination chemotherapy. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 89 | |
| All comers | Single metastasis | Resection or stereotactic radiotherapy with curative intent. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 40 | |
| HR-positive | Neuroendocrine carcinoma of unknown primary | Platinum-etoposide as for extrapulmonary neuroendocrine carcinoma; somatostatin analogues and radioligand therapy for well-differentiated tumours. | ESMO Clinical Practice Guideline on cancer of unknown primary 2023 | 82 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.